An advisory panel of the US Food and Drug Administration has recommended that the agency approve tofacitinib, a JAK inhibitor which has been developed to treat rheumatoid arthritis. A formal decision is expected in August, according to Pfizer. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
